Abstract
Background This study measured the long-term health-related quality of life of non-hospitalised COVID-19 cases with PCR-confirmed SARS-CoV-2(+) infection using the recommended instrument in England (the EQ-5D).
Methods Prospective cohort study of SARS-CoV-2(+) cases aged 12-85 years and followed up for six months from 01 December 2020, with cross-sectional comparison to SARS-CoV-2(-) controls. Main outcomes were loss of quality-adjusted life days (QALDs); physical symptoms; and COVID-19-related private expenditures. We analysed results using multivariable regressions with post-hoc weighting by age and sex, and conditional logistic regressions for the association of each symptom and EQ-5D limitation on cases and controls.
Results Of 548 cases (mean age 41.1 years; 61.5% female), 16.8% reported physical symptoms at month 6 (most frequently extreme tiredness, headache, loss of taste and/or smell, and shortness of breath). Cases reported more limitations with doing usual activities than controls. Almost half of cases spent a mean of £18.1 on non-prescription drugs (median: £10.0), and 52.7% missed work or school for a mean of 12 days (median: 10). On average, all cases lost 15.9 (95%-CI: 12.1, 19.7) QALDs, while those reporting symptoms at month 6 lost 34.1 (29.0, 39.2) QALDs. Losses also increased with older age. Cumulatively, the health loss from morbidity contributes at least 21% of the total COVID-19-related disease burden in England.
Conclusions One in 6 cases report ongoing symptoms at 6 months, and 10% report prolonged loss of function compared to pre-COVID-19 baselines. A marked health burden was observed among older COVID-19 cases and those with persistent physical symptoms.
summary Losses of health-related quality of life in non-hospitalised COVID-19 cases increase by age and for cases with symptoms after 6 months. At a population level, at least 21% of the total COVID-19-related disease burden in England is attributable to morbidity.
Competing Interest Statement
The Immunisation Department at PHE (and the UK Health Security Agency as the legal successor) has provided post-marketing surveillance reports to Marketing Authorisation Holders which they are required to submit to the UK Licensing authority in compliance with their Risk Management Strategy. A cost recovery charge is made for these reports.
Funding Statement
This work was supported by Public Health England (PHE) and its legal successor, the UK Health Security Agency (UKHSA), which is an executive agency of the Department of Health and Social Care (DHSC). The authors had sole responsibility for the study design, data collection, data analysis, data interpretation, and writing of the report. MJ was supported by the NIHR HPRU in Immunisation at the London School of Hygiene and Tropical Medicine in partnership with PHE/UKHSA (grant code NIHR200929) and the European Commission (EC) Horizon 2020 research and innovation programme - project EpiPose (grant agreement No 101003688). FGS, EvL, RME, WJE and MJ were supported by the NIHR HPRU in Modelling and Health Economics, a partnership between PHE/UKHSA, Imperial College London and LSHTM (grant code NIHR200908). RME was also supported by HDR UK (grant: MR/S003975/1). The views expressed are those of the authors and not necessarily those of DHSC, the EC, the National Health Service (NHS), NIHR, or PHE/UKHSA. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
A waiver of ethical approval was received for this study from the PHE Research Support and Governance Office. Ethical approval for this study was not required as the collection of information on patients quality of life is part of the statutory tasks and routine surveillance activities of Public Health England and its legal successor, the UK Health Security Agency.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding source This work was supported by Public Health England (PHE) and its legal successor, the UK Health Security Agency (UKHSA), which is an executive agency of the Department of Health and Social Care (DHSC). The authors had sole responsibility for the study design, data collection, data analysis, data interpretation, and writing of the report. MJ was supported by the NIHR HPRU in Immunisation at the London School of Hygiene and Tropical Medicine in partnership with PHE/UKHSA (grant code NIHR200929) and the European Commission (EC) Horizon 2020 research and innovation programme - project EpiPose (grant agreement No 101003688). FGS, EvL, RME, WJE and MJ were supported by the NIHR HPRU in Modelling and Health Economics, a partnership between PHE/UKHSA, Imperial College London and LSHTM (grant code NIHR200908). RME was also supported by HDR UK (grant: MR/S003975/1). The views expressed are those of the authors and not necessarily those of DHSC, the EC, the National Health Service (NHS), NIHR, or PHE/UKHSA. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Potential conflicts of interest The Immunisation Department at PHE (and the UK Health Security Agency as the legal successor) has provided post-marketing surveillance reports to Marketing Authorisation Holders which they are required to submit to the UK Licensing authority in compliance with their Risk Management Strategy. A cost recovery charge is made for these reports.
Data Availability
A waiver of ethical approval was received for this study from the PHE Research Support and Governance Office. Ethical approval for this study was not required as the collection of information on patients quality of life is part of the statutory tasks and routine surveillance activities of Public Health England and its legal successor, the UK Health Security Agency.
